PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Canrenoate→

Canrenoate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
C22H29O4−
Molecular weight
357.5 g/mol
Drug class
Potassium-sparing mineralocorticoid receptor antagonist prodrugcanrenone precursor
Mechanism of action
Canrenoate is converted to canrenone, which antagonises mineralocorticoid (aldosterone) receptors in the distal nephron, increasing sodium and water excretion while reducing potassium excretion.
Indications / reported uses
  • Treatment of oedema and hyperaldosteronism-related conditions in countries where intravenous or oral canrenoate products are authorised; specific indications and routes are jurisdiction-specific

Sources: NLM MeSH — Potassium canrenoate/canrenoate · PubMed — Canrenoate mineralocorticoid receptor antagonist · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Canrenoate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Canrenoate Permitted Daily Exposure (PDE) report (the Canrenoate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Canrenoate Occupational Exposure Limit (OEL) report (the Canrenoate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.